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Abstract: The Hedgehog (Hh) pathway is critical for cell differentiation, tissue polarity, 
and stem cell maintenance during embryonic development, but is silent in adult tissues under 
normal conditions. However, aberrant Hh signaling activation has been implicated in the 
development and promotion of certain types of cancer, including basal cell carcinoma (BCC), 
medulloblastoma, and gastrointestinal cancers. In 2015, the US Food and Drug Administra-
tion (FDA) approved sonidegib, a smoothened (SMO) antagonist, for treatment of advanced 
BCC (aBCC) after a successful Phase II clinical trial. Sonidegib, also named Odomzo, is the 
second Hh signaling inhibitor approved by the FDA to treat BCCs following approval of the 
first SMO antagonist vismodegib in 2012. What are the major features of sonidegib (mecha-
nism of action; metabolic profiles, clinical efficacy, safety, and tolerability profiles)? Will the 
sonidegib experience help other clinical trials using Hh signaling inhibitors in the future? In this 
review, we will summarize current understanding of BCCs and Hh signaling. We will focus on 
sonidegib and its use in the clinic, and we will discuss ways to improve its clinical application 
in cancer therapeutics.
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Introduction
Since the discovery of the Hedgehog (Hh) gene in the fruit fly in 1980, significant 
progress has been made in our understanding of the role of its signaling pathway, 
not only in the regulation of cell differentiation during development, but also in the 
development of cancer.1 Three homologues of the Hh gene have been identified: 
Sonic hedgehog (Shh), Desert hedgehog (Dhh), and Indian hedgehog (Ihh).2–6 The 
Hh signaling pathway is highly conserved, including the ligands (Shh, Dhh, Ihh), 
patched receptors (PTCH1, PTCH2), signal transducer smoothened (SMO), and Gli 
transcription factors (Gli1, Gli2, Gli3). Without binding of Hh ligand to the trans-
membrane patched receptor, patched will inhibit the function of SMO. Binding of 
Hh ligand releases this inhibition, allowing SMO to signal downstream and activate 
the Gli transcription factors. Gli can bind to the promoter regions of their target 
genes, regulating their expression.7–9 Studies have revealed additional mechanisms 
controlling signaling of this pathway, such as the role of cilium in Hh signaling,10–12 
co-receptors of Hh molecules,13–15 potential molecules mediating PTCH1-mediated 
SMO suppression,16 and ways for Gli transcription factor regulation.17–20 This pathway 
is referred to as canonical signaling. In addition, Gli transcription factors can be also 
activated in the noncanonical fashion by KRAS, TGFβ, PI3K, and PKC (Figure 1). 
Any mutation in these pathways may lead to abnormal fetal development as well as 
malignant disease in adults.
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Since its connection to human cancer development, 
numerous compounds have been discovered to have inhibi-
tory effects on Hh signaling. As of yet, two compounds 
(vismodegib and sonidegib) have been approved by the US 
Food and Drug Administration (FDA) to treat basal cell car-
cinomas (BCCs). In this review, we will focus on sonidegib: 
its discovery, mechanism of action, and clinical utility for 
advanced BCCs (aBCCs).
The Hh pathway in cancer 
development
The Hh signaling pathway was first linked to cancer develop-
ment when it was found that mutations in PTCH1 are linked 
to a rare and hereditary form of BCC, basal cell nevus syn-
drome (BCNS), also known as Gorlin syndrome.21,22 Gorlin 
syndrome has two major phenotypes: developmental defects 
and an increased risk of developing cancers that are associ-
ated with Hh signaling mutations, including BCC, medullo-
blastoma, rhabdomyosarcoma, and meningioma.
The majority of BCCs and other Gorlin syndrome 
associated cancers, including rhabdomyosarcomas, menin-
giomas, and medulloblastomas, have mutations in PTCH1, 
SMO, and other Hh pathway molecules or an elevation in 
Hh target gene expression. Based on these findings, it has 
been suggested that Hh signaling plays several roles in can-
cer development: as a tumor driver, tumor promoter, tumor 
metastasis promoter, or cancer stem cell promotor. As 
previously discussed, activating mutations of Hh signaling 
can drive the development of BCCs, medulloblastomas, 
rhabdomyosarcomas, gastrointestinal stromal-like tumors, 
and Barrett’s esophagus.23 In small cell lung cancer 
(SCLC), Hh signaling can promote cancer development 
but cannot drive tumor formation. In pancreatic cancers, 
inhibiting Hh signaling can prevent tumor invasion and 
metastasis. Finally, Hh signaling can regulate cancer stem 
cell numbers as well as the tumor microenvironment, creat-
ing conditions that promote tumor growth. This role of Hh 
signaling can be found in leukemia and liver cancer, and 
is often responsible for the recurrence of cancer through 
resistance to chemotherapy and radiotherapy.24–33 Dys-
regulation of any component of the Hh pathway leading to 
its aberrant activation can result in malignant conditions 
through these mechanisms.
BCC
BCC is the most common form of skin cancer and among 
the most commonly diagnosed forms of cancer in the USA, 
with over one million cases per year.34 Although it has a low 
risk for metastasis, it is a slow growing tumor that causes 
morbidity via its proximity to critical facial structures. It also 
has a tendency to relapse, occur in multiple locations, and 
invade and destroy local tissues.
Classification of BCCs is dependent on prognostic 
factors including tumor size, histological characteris-
tics, tumor location, margins, and recurrence. Usually, 
superficial BCC is treatable with nonsurgical techniques 
including photodynamic therapy and topical imiquimod or 
5-fluorouracil treatment, or by surgical techniques including 
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Figure 1 Canonical Hh signaling and noncanonical Hh signaling. 
Abbreviations: Hh, Hedgehog; PTCH, patched; Shh, Sonic hedgehog; SMO, smoothened.
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electrodessication, Mohs micrographic surgery, excisional 
surgery, cryosurgery, or laser surgery. However, invasion of 
the BCC into surrounding muscle, bone, or cartilage results 
in locally advanced BCC. Unfortunately, these tumors are 
incurable, or not treatable by surgery or radiotherapy. Suc-
cessful treatment is dependent on tumor progression, a history 
of previous treatments, and any medical contraindications. 
Cytotoxic chemotherapy has not been approved for treatment 
of nonresectable BCC, and these patients can only benefit 
from palliative care. Metastatic BCC (mBCC) is extremely 
rare, with an incidence of up to 0.55% of cases. It commonly 
affects the regional lymph nodes, lungs, and liver. The prog-
nosis of mBCC is very poor, with a mean survival between 8 
months and 3.6 years. Both locally advanced BCC (laBCC) 
and mBCC can be collectively referred to as aBCC. Unfor-
tunately, treatment of aBCC was nonexistent until the recent 
development of Hedgehog pathway inhibitors (HPIs).
There are a number of small molecules targeting SMO, 
with potent activity to treat Hh-driven aBCC. Although 
several compounds are shown to target Gli transcription 
factors or the Hh molecules, their specificity and potency 
to treat aBCC have not been demonstrated in clinical 
trials. Currently, seven small molecule inhibitors are under 
clinical trial or have been approved to target SMO in the 
treatment of Hh-driven cancers. These SMO inhibitors 
include cyclopamine derivatives IPI-926 (saridegib), GDC-
0449 (vismodegib), BMS833923 (XL-139), PF04449913 
(glasdegib), LY2940680 (taladegib), LEQ506, TAK-441, 
and LDE-225 (NVP-LDE225, sonidegib).8,35–37
Discovery, modifications, and 
mechanism of action of sonidegib
Sonidegib, marketed as Odomzo by Novartis, was approved 
by the FDA in July 2015 as a 200 mg oral pill for treatment of 
recurrent aBCC, or aBCC in patients who are not eligible for 
surgery or radiation therapy. It is currently being investigated 
for use in the treatment of other cancer types.
Sonidegib belongs to a class of biphenyl carboxamides 
and was discovered as an SMO antagonist using a high-
throughput screen in vitro.38 A structure–activity relationship 
study was performed using variations in three regions of the 
originally identified molecule, compound 1, which is the 
core structure of sonidegib (Figure 2A). First, modification 
to region A with a nitrogen in the pyridine moiety and the 
addition of cis-dimethyl groups on the morpholine ring 
helped to mitigate the risk of widespread toxicity by reduc-
ing electron density. Next, the addition of a methyl group in 
region B increases the potency to inhibit SMO. Furthermore, 
a modification to region C with –OCF
3
 at the R
4
 position 
yielded 5 m (NVP-LDE225; Figure 2B), with the most 
favorable pharmaceutical properties, ADMET (absorption, 
distribution, metabolism, excretion, and toxicity) properties, 
and pharmacokinetics.
Sonidegib interacts with SMO in the drug-binding pocket, 
where it acts as an antagonist, preventing downstream 
activation of Hh pathway signaling (Figure 3).39–42 Based 
on the recently reported SMO structure, there are numerous 
residues in the drug-binding pocket interacting with a SMO 
antagonist. It was reported that residues from the extracellular 
tips of helices I, II, V, and VII interact with LY2940680. The 
most notable interaction is between R400 of helix V and 
the compound via the phthalazine ring. Several structured 
water molecules in the ligand pocket are also critical for the 
interactions, including R400, H470, D473, E518, and N521 
side chains. Mutations within the pocket, including Q476 
and D473, prevent sonidegib binding. Other mutations, 
including S533 and W535, cause conformational changes in 
SMO, blocking sonidegib from accessing the drug-binding 
Figure 2 Generation of Sonidegib.
Notes: (A) The structure of compound #1 from a cell-based screening. (B) The structure of sonidegib, which has high biological potency.
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pocket.42 These mutations have been found to confer resis-
tance to sonidegib.43
Metabolic profiles and 
pharmacokinetics of sonidegib
Sonidegib has a unique metabolic profile. While the T
max
 for 
sonidegib in blood and plasma is only 2–3 h, the T
max
 for its 
main metabolite M48 is 60 h, suggesting that sonidegib is 
slowly metabolized by the body. The T
1/2
 for sonidegib is 
over 14 days.44 Similarly, the T
max
 for vismodegib is ~2 h with 
T
1/2
 in the plasma around 7–14 days.45,46 Vismodegib is also 
a slowly metabolized compound, with the major metabolite 
M1 appearing 24 h after administration.
Sonidegib has multiple pharmacokinetic properties that 
make it an effective therapeutic agent.47 It is highly bound 
to plasma proteins (over 99%) in humans. It shows between 
69% and 102% oral bioavailability when given in solution. 
Sonidegib also shows high tissue penetration and favorable 
blood–brain barrier penetration, making it a viable treatment 
for medulloblastoma. It did not show cytochrome P450 
inhibition or induction, minimizing its potential to interact 
with the metabolism of other drugs. In screens against a 
panel of receptors, channels, transporters, kinases, and pro-
teases, no activity was identified, limiting its potential for 
off-target effects.38
Sonidegib has a pH-dependent solubility, with a low 
solubility at high pH.38,48 A Phase I study in Asian patients 
showed that they have a lower maximum tolerated dose 
(MTD) due to more severe creatinine kinase (CK) eleva-
tion.49 Thus, dosing considerations should be taken when 
treating individuals of East Asian descent as compared to 
the Western population.
Clinical trials with sonidegib
Sonidegib was approved for the treatment of aBCC follow-
ing the demonstration of its efficacy in the Phase II BOLT 
(BCC outcomes with LDE225 treatment) clinical trials.50 
Since then, additional clinical trials have been completed to 
assess the efficacy of sonidegib in aBCC treatment.51 The 
BOLT study included long-term follow-up data of patients 
treated with sonidegib. This was a multicenter, randomized, 
double-blind study in which patients took either 200 or 
800 mg sonidegib daily. Over 50% of patients saw objective 
responses in the 200 mg study arm, whereas the response 
with the 800 mg study arm was lower. Out of the 94 patients 
who had laBCC and responded to the drug, 18 progressed or 
died, while more than half had a response for .6 months. 
More importantly, 80% of patients with mBCC showed and 
maintained an objective response. Long-term follow-up of 
patients in this study showed that 200 mg sonidegib has 
a better treatment profile over 800 mg, and it maintains 
extended efficacy in the treatment of aBCC.
Sonidegib efficacy has also been studied to determine the 
objective response rate, progression-free survival, and time 
to tumor response. Exposure-safety analysis was performed 
at doses ranging from 100 to 3,000 mg once daily and 
250–750 mg twice daily. Both responders and nonresponders 
showed similar plasma concentration levels, but there was 
no correlation between the dosage and probability of tumor 
response. Similarly, increasing exposure did not show an 
improvement in progression-free survival nor in time to 
tumor response.52 Thus, patients who fail to respond to lower 
doses may not benefit from an increase in dose. These results, 
consistent with other studies, suggest that a 200 mg dose of 
sonidegib can be used to achieve clinical efficacy and avoid 
potential adverse events associated with drug toxicity.
Interestingly, the adaptive immune response is promoted 
in patients with aBCC treated with sonidegib or vismodegib. 
Immunological markers, including Ber-Ep4, BCL-2, CD4, 
CD8, and HLA-DR-class II, were measured in aBCC after 
treatment with vismodegib (n=22) or sonidegib (n=1). Follow-
ing 4 weeks of treatment, Ber-EP4 and BCL-2 expression in 
tumors decreased, while HLA expression was upregulated on 
residual tumor cells, leading to the recruitment of CD8+ cyto-
toxic T cells into the tumor mass. Analysis with quantitative 
polymerase chain reaction revealed that expression of immune 
response-regulating genes was altered, which is consistent 
with our previous study that the Hh pathway is responsible 
for suppressing the immune response, and SMO antagonists 
relieve the suppression.52,53 Although this study was severely 
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Figure 3 Sonidegib interacts with the drug-binding pocket of SMO, which mainly 
consists of three amino acids: arginine (R) 473, arginine (R) 400, and glutamic acid 
(e) 518.
Abbreviation: SMO, smoothened.
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limited by the low number of patients treated with sonidegib, 
the result supports the role of Hh signaling for the immune 
suppressive microenvironment as well as the possibility to 
combine immune modifiers with Hh signaling inhibition to 
achieve extended tumor control.
Although sonidegib has been shown to be effective in the 
treatment of aBCC, its use in patients previously treated with 
vismodegib will not be effective. The majority of patients 
who were treated with sonidegib following resistance to 
vismodegib experienced progressive disease; these patients 
were found to have SMO mutations that prevented the 
antagonist effects of SMO antagonists.43
One method to detect tumor shrinkage after sonidegib 
treatment is the use of noninvasive imaging technologies 
reflectance confocal microscopy and high-definition optical 
coherence tomography. In patients who showed complete 
response, pseudocystic structures, or areas of necrosis and 
fibrosis were observed by these noninvasive techniques.54 The 
treatment effect can be observed without exposing the patients 
to radiation over multiple occasions. However, residual tumor 
cells were often found in some cases. Thus, caution should 
be taken, as always, when using imaging as a tool for guid-
ing treatment. It should be used in concert with other tools to 
determine the best course of action for the patient.
These studies consistently show sonidegib efficacy in the 
treatment of aBCC. Sonidegib shows strong promise in the 
long-term treatment of aBCC, especially when combined 
with other therapies, including immune modifiers.
There are significant interests in shifting toward the appli-
cation of sonidegib in the treatment of other cancers renal cell 
carcinoma, lung cancer, myeloid leukemia, pancreatic cancer, 
medulloblastoma, ovarian cancer, and lymphoma. Most of 
the studies, however, were performed in mouse models.
Sonidegib has been shown to be efficacious in the treat-
ment of SCLC. The Hh pathway has been linked to tumor 
initiation in SCLC. A Phase I study determined the MTD 
of sonidegib for the treatment of SCLC in combination with 
etoposide/cisplatin chemotherapy agents. Patients received 
up to six, 21-day cycles of etoposide/cisplatin with 400 or 
800 mg daily sonidegib. A total of 800 mg was determined to 
be the MTD, with 79% of patients showing partial response.55 
Interestingly, a high efficacy is observed when a higher dose 
of sonidegib is used.
Together, these studies show the potential for sonidegib to 
treat aBCC and possibly other cancer types. There is evidence 
to indicate that sonidegib treatment along with other agents 
could be more efficacious. While sonidegib is an effective 
drug, its safety profile must be evaluated for each potential 
treatment indication.
Safety, tolerability, and adverse 
effects of sonidegib
The BOLT study first assessed the safety and tolerability of 
sonidegib in the treatment of aBCC.50 In aBCC treatment 
with sonidegib, almost all patients experienced at least 
one adverse event. The most commonly observed adverse 
events in patients receiving sonidegib (200 or 800 mg) 
include (from most common to least common): muscle 
spasms, alopecia, dysgeusia, nausea, increased CK, fatigue, 
decreased weight, diarrhea, decreased appetite, myalgia, 
and vomiting (Table 1). Adverse events leading to dose 
interruptions, reductions, or treatment discontinuation were 
less frequent with the 200 mg/day dose in comparison with 
the 800 mg dose. Grade 1/2 muscle spasms, dysgeusia, 
nausea, and alopecia were the most common causes of 
discontinuation. CK elevation was the most common grade 
3/4 event, occurring in 6% of patients taking the 200 mg 
dose; women show a lower risk of CK abnormality than 
men.52 Furthermore, CK elevations were observed at low 
doses in Japanese patients, which resulted in their lower 
MTD of sonidegib.48,49 Serious adverse events, including 
rhabdomyolysis and very high CK, were very rarely associ-
ated with sonidegib. None of the deaths in the study were 
associated with sonidegib treatment.50,51
Around 70% of patients taking 200 mg sonidegib were 
able to stay on treatment for at least 8 months. Despite seeing 
tumor response, many patients discontinued treatment, citing 
severe discomfort. However, over half of those who discon-
tinued experienced only grade 1/2 adverse events. Many of 
these patients did not feel the need to suffer through treat-
ment after already seeing benefits.53 Management strategies 
for adverse events combined with improved patient educa-
tion regarding treatment plans may lead to increased patient 
acceptance and tolerance of sonidegib therapy.
Adverse events associated with treatment are linked to 
the inhibition of the Hh pathway in normal tissues. Although 
adverse events may be mild, the long-term experience can 
cause patients to experience decreased quality of life, treat-
ment interruption, and discontinuation before achieving any 
therapeutic benefit. These adverse events may have a signifi-
cant impact on the clinical outcome of the patient. Improved 
knowledge of the mechanisms and management of adverse 
events will help physicians to better guide their treatments 
with appropriate prevention or intervention.
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Muscle spasms can be relieved by passive stretching, 
heating, cryotherapy, exercise, electrical stimulation, 
splinting, and changing sitting or sleeping positions. Phar-
macologic treatments include calcium channel blockers, 
nerve stabilizers, or magnesium supplements. A number of 
other pharmaceuticals have been recommended, especially 
for cases in which muscle spasms spread to the abdomen. 
Almost 40% of patients taking 200 mg sonidegib experience 
dysgeusia, often leading to weight loss. Delta-9-tetrahydro-
cannabinol showed promise in improving taste sensation 
and appetite. Consulting with a dietician can be beneficial 
for these patients and has been shown to decrease the onset 
of dysgeusia. Hair loss (alopecia) in these patients can 
affect their psychosocial well-being, leading to problems 
such as depression.
Sonidegib and other Hh signaling inhibitors block fol-
licles from starting the anagen growth phase after shedding 
of hair in telogen, leading to extended, or in some cases, 
permanent hair loss. Minoxidil and dihydrotestosterone 
inhibitors may help promote hair growth. Weight loss can 
be associated with the disease process or the treatment itself. 
It usually begins at least 6 months following the beginning 
of treatment. Again, dieticians and supplementation can be 
helpful in these cases.
Table 1 Summary of smoothened antagonists
Name LDE225 GDC0499 IPI-926 PF-04449913 TAK-441 BMS833923/
XL-139
LY-2940680 LEQ506
Drug name Sonidegib/
Odomzo
vismodegib/
erivedge
Saridegib Glasdegib Taladegib
CAS number 956697-53-3 879085-55-9 1037210-93-7 1095173-27-5 1186231-83-3 1059734-66-5 1258861-20-9 1204975-42-7
Mw 485.5 421.3 504.3 374.4 576.2 473.2 512.5 432.56
NCT number NCT02111187; 
NCT02195973; 
NCT02086513; 
NCT02151864; 
NCT02138929; 
NCT02086552; 
NCT02358161; 
NCT02129101
NCT02639117; 
NCT02337517; 
NCT01835626; 
NCT02956889; 
NCT02694224; 
NCT01601184; 
NCT02648048; 
NCT02690948; 
NCT02593760; 
NCT02436408; 
NCT02781389; 
NCT02091141; 
NCT02073838; 
NCT02523014; 
NCT01878617; 
NCT02465060; 
NCT02693535; 
NCT02788201
NCT01383538 NCT01841333; 
NCT02367456; 
NCT02038777; 
NCT01546038; 
NCT02226172
1204073 NCT01218477 NCT02784795; 
NCT02530437
NCT1106508
Recommended 
dose
400 mg qd 150 mg qd 160 mg qd 100 mg qd MTD  
1,600 mg qd
100 mg qd 200 mg qd 250 mg bid
Binding to SMO Drug-binding 
pocket
Drug-binding 
pocket
Drug-binding 
pocket
Drug-binding 
pocket
Not 
determined 
(possibly not 
in the pocket)
Not known Drug-binding 
pocket
Not known 
(possibly 
not in the 
pocket)
Adverse events Muscle spasms; 
alopecia; 
dysgeusia; 
nausea; 
creatine kinase 
elevation; 
vomiting/
weight loss/
diarrhea
Muscle spasms; 
weight loss; 
alopecia; 
fatigue; low 
appetite; 
diarrhea
Liver function 
abnormality; 
fatigue; muscle 
spasms; 
vomiting/
nausea; rash; 
diarrhea
Dysgeusia; 
fatigue; low 
appetite; 
dizziness; 
dehydration; 
diarrhea
Hyponatremia; 
fatigue; 
dysgeusia; 
alopecia; 
muscle spasms
Not available Not available Not available
Single agent (S) or 
combined therapy (C)
S, C S, C C S, C S S S, C S
Abbreviations: MTD, maximum tolerated dose; SMO, smoothened; CAS, Chemical Abstracts Service; Mw, molecular weight; NCT, National Clinical Trial; bid, twice 
daily; qd, once daily.
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Fatigue is often a result of the culmination of other adverse 
events, including the muscle spasms and decreased appetite. 
Pharmacologic interventions may help, but physical activity, 
psychosocial intervention, sleep therapy, and nutritional 
supplementation may also help. Nausea is one of the earliest 
reported adverse events. Sonidegib was reported to be a 
moderate to high emetogenic agent. Serotonin inhibitors, 
antipsychotics, and other pharmaceutical agents can be 
provided for their antiemetic effects. In addition to regular 
monitoring of CK levels before and during treatment, health 
care providers should watch for symptoms of rhabdomyolysis, 
including muscle pain, tenderness, and weakness.56 Despite 
the multitude of adverse events patients may experience, 
application of these strategies can improve patient tolerance 
of treatment.
In the treatment of SCLC with sonidegib, the adverse 
events are markedly different from those seen in aBCC. This 
may be the result of a higher recommended dose of sonidegib 
used to treat SCLC (800 mg) versus aBCC (200 mg). SCLC 
patients often experience grade 3/4 toxicities including 
anemia, neutropenia, CK elevation, fatigue, and nausea. The 
toxicity of sonidegib led to discontinuation of treatment in 
one patient.55
The safety profile of sonidegib in cancers besides aBCC 
has not been thoroughly studied as of yet. As more of these 
studies move toward human trials, we can expect to see fur-
ther evaluation of safety and tolerability, which will likely 
vary among different cancer types. However, the safety 
studies done in aBCC patients illustrate that although the 
drug is effective, it does have significant related adverse 
events. Many patients discontinue due to the long-term 
grade 1/2 events they experience, indicating lower patient 
quality of life, acceptability, and adherence. Nevertheless, 
the benefit of the drug is much greater than the potential 
side effects, and through patient education and management 
strategies, adverse events can be minimized and treatment 
can be continued further to improve the outcomes.
Other SMO inhibitors
Vismodegib is a first-in-class HPI that was approved by the 
FDA in 2012 for the treatment of aBCC, and it is currently 
being studied for use in other cancers, including colorectal 
cancer, pancreatic cancer, and medulloblastoma. Vismodegib 
acts in the same drug-binding pocket as sonidegib. In its Phase I 
study, about half of the patients treated with vismodegib 
showed tumor response. Patients in the Phase II study 
showed lower tumor response and many experienced serious 
adverse events.37 However, over 50% of patients experience 
refractory aBCC and a portion of initial responders develop 
resistance. In these patients, resistance to sonidegib is also 
predicted.43 Adverse events associated with vismodegib treat-
ment include grade 3 fatigue, hyponatremia, muscle spasms, 
and atrial fibrillation. Although vismodegib is fairly effica-
cious and has a similar safety profile to that of sonidegib, it 
seems to have more severe adverse events.
Cyclopamine was among the first SMO antagonists to 
be developed. It functions as an inverse agonist of SMO. 
However, it exhibits poor oral solubility and has many off-
target adverse effects, making it a poor candidate for use in 
human cancer treatment. IPI-262, BMS-833923, Taladegib, 
PF-04449913, TAK-441, and LEQ506 are being investigated 
in clinical trials for treatment of aBCC.37 In a study compar-
ing the pharmacologic properties of these drugs, there was a 
significant variation in their inhibiting potencies as well as 
their ability to be used in a topical application. For example, 
LEQ-506 and TAK-441 are favorable in the treatment of 
minimally invasive BCC due to their properties in a topical 
formulation and their low side effects. In contrast, sonidegib 
and vismodegib have stronger side effects, limiting their use 
in less invasive BCCs.57 The development of these SMO 
inhibitors promises the coming of therapies that will offer 
diverse properties in terms of treatment indications, clinical 
efficacy, and safety profiles.58–60
Perspectives
The evaluation of sonidegib’s clinical efficacy and its safety 
profile indicate its promise for treatment of aBCC and pos-
sibly for other cancer types. A large proportion of patients see 
clinical benefits with only mild to moderate adverse events. 
Despite the rare serious adverse events, the complete response 
rate (~30%) is fairly low for a tumor type driven mostly by 
mutations in the PTCH1 gene. The response rate for mBCC 
is even worse (,5%). There are a number of reasons for the 
different responses from BCC patients. First, the genetic 
mutations underlying the Hh signaling activation in the 
BCCs were not known at the time of clinical trials. For gene 
mutations in SMO or SUFU, which may contribute to ~20% 
of tumors, sonidegib and vismodegib will not be effective. 
Second, the response of patients to drugs varies significantly; 
detailed analysis of the biomarkers following the treatment 
may reveal additional mechanisms as to why some patients 
respond better than others. Third, while Hh signaling is the 
single most important pathway for BCC development, other 
signaling pathways do play important roles, such as p53 gene 
mutations. Fourth, drug resistance occurs frequently follow-
ing treatment with SMO antagonists such as vismodegib. 
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The resistance may be from mutations of SMO itself or other 
important players such as PI3K signaling.
Thus, there is still a lot of work needed for better treat-
ment of BCCs using SMO inhibitors. Patient education and 
management strategies can significantly improve a patient’s 
way of life during treatment. When developing treatment 
plans, an important consideration is the propensity of patients 
to develop resistance. While a large proportion of patients 
show resistance, evaluating tumor response regularly will 
allow a physician to determine whether sonidegib is the 
appropriate treatment. Furthermore, genotyping patient 
tumors could identify patients with mutations leading to 
resistant tumors and help to avoid unnecessary treatment 
with a SMO inhibitor.
Sonidegib may have a strong role as an adjunct therapy in 
the treatment of other cancers. With its observed potentiating 
effects in multiple cancer types, the approval of additional 
clinical applications for sonidegib can be anticipated. Nev-
ertheless, although sonidegib is a potent HPI, it will not be 
effective in suppressing noncanonical Hh signaling since these 
signaling events bypass SMO-dependent signaling (Figure 1). 
Growing evidence suggests that certain cancer types, including 
pancreatic cancer, may exhibit aberrant noncanonical pathway 
activation. Thus, we may see benefit from the development 
of a common downstream Hh signaling molecule antagonist, 
such as inhibitors for the Gli transcription factors.
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